Clinical Trials Logo

CML clinical trials

View clinical trials related to CML.

Filter by:
  • Not yet recruiting  
  • Page 1

NCT ID: NCT06423911 Not yet recruiting - Clinical trials for Chronic Myeloid Leukemia

A Phase 3 Registrational Study of Olverembatinib (HQP1351) in Patients With CML

POLARIS-2
Start date: May 2024
Phase: Phase 3
Study type: Interventional

A Global Multicenter, Open Label, Randomized, Phase 3 Registrational Study of Olverembatinib (HQP1351) in Patients with Chronic Phase Chronic Myeloid Leukemia (POLARIS-2)

NCT ID: NCT06047886 Not yet recruiting - Clinical trials for Myelodysplastic Syndromes

CD34 Selection Using the Automated CliniMACS Prodigy

Start date: June 2024
Phase: Phase 1
Study type: Interventional

Patients with graft failure or delayed engraftment may benefit from a hematopoietic stem cell boost or an additional hematopoietic stem cell transplantation procedure. In such settings standard immune suppression strategies are avoided due to their myelosuppressive nature. Therefore those patients are at increased risk of graft versus host disease, and the infusion of a CD34 selected graft would reduce such a risk. The infusion of CD34 selected graft using CliniMACS plus is currently FDA FDA-approved indication for acute myeloid leukemia. However, the use of the Prodigy would streamline the processing, in terms of hands-off procedure, allowing to provision of this product to the patients without strains on the cell therapy lab team. This procedure has been demonstrated safe and effective in several single-center studies and is currently in advanced phase investigation in several studies for malignant and non-malignant conditions.